Loading clinical trials...
Loading clinical trials...
The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL),...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
BeiGene
NCT06149286 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more
NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more
NCT06442475 · Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, and more
NCT07448324 · Marginal Zone Lymphoma(MZL)
Ucsf Fresno University of California San Francisco Fresno
Fresno, California
Kaiser Permanente Southern California
Irvine, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions